In summary, some of the NAT2 variants, which are associated with elevated plasma lipid and cholesterol levels, also have been identified as risk alleles for cardiometabolic disorders, including coronary artery disease, myocardial infarction, and metabolic syndrome, as well as increased cardiovascular drug use. This evidence concerns the gene NAT2 and metabolic syndrome.